Dyax and Fovea Strike Drug Pact

Xconomy Boston — 

Biotech firm Dyax (NASDAQ:DYAX), based in Cambridge, MA, says that it has struck an exclusive license deal with French drug firm Fovea Pharmaceuticals to develop a version of Dyax’s lead drug ecallantide for eye diseases. Separately, Dyax is pursuing U.S. approval of ecallantide for a rare blood disease called hereditary angioedema (HAE). Last week an FDA panel recommended approval of the protein drug for HAE, and the agency is expected to decide whether to approve the drug by March 23.